Report LibraryAll Reports
Datamonitor Healthcare CNS Disease Analysis: Parkinson’s Disease
March 29, 2021
Duopa is among the most lucrative drugs currently available in the PD market. A contributing factor to the drug’s successful market
penetration is the clinical efficacy data achieved in trials, where Duopa treatment significantly reduced “off” periods in PD patients compared
to the standard of care, Sinemet (carbidopa/levodopa). Duopa, also a carbidopa/levodopa combination, is delivered directly and continuously
into the intestines by a pump for up to 16 hours per day, thus reducing or even eliminating fluctuations and “off” periods. The procedure,
however, is one of the most invasive in this market and comes with the usual risks of surgical complications. Duopa also has one of the highest
price tags in the PD market, but since payers view its cost-effectiveness ratio positively, AbbVie looks set to maintain fruitful returns on the
Acadia’s Nuplazid, the first and only US-approved drug for Parkinson’s disease psychosis (PDP), scores well commercially in Datamonitor Healthcare’s drug assessment model. In pivotal trials, Nuplazid demonstrated significant efficacy in reducing the hallucinations and delusions associated with PDP, and through its non-dopaminergic mechanism it has shown no negative impacts on motor function. Furthermore, most other atypical antipsychotics are contraindicated for PDP, with none approved by the FDA for this specific condition. Acadia reported $441.8m in sales for Nuplazid in 2020, and this is expected to increase substantially over the coming decade given the lack of competition in this segment and the drug’s ongoing clinical development in other indications.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Parkinson's Disease (PD)|